Maxigen Biotech Inc. (TWSE: 1783)
Health Care · Biotechnology · TW
NT$40.40
+0.25% today · -7.2% 1Y
Maxigen Biotech Inc. (TWSE: 1783) operates in the Biotechnology industry within the Health Care sector. The company is valued at $113.78M and employs 127 people.
Over the last twelve months the share price has lost 7.2%, trading between 37.80 and 48.85.
Tweenvest scores Maxigen Biotech Inc. across four factors: quality 74/100, value 87/100, dividend 41/100. Its strongest factor is value.
1783 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $113.78M
- Revenue (TTM)
- $26.32M
- P/E
- 12.56
- EPS
- 3.22
- Dividend yield
- 4.95%
- Beta (5Y)
- 0.38
- 52-week high
- NT$48.85
- 52-week low
- NT$37.80
- Avg volume (3M)
- —
- Shares outstanding
- 89.68M
- Employees
- 127
- Next earnings
- —
About Maxigen Biotech Inc.
Maxigen Biotech Inc. (MBI) is a company dedicated to the research, development, production, and global commercialization of advanced biomedical and skincare solutions. Its extensive biomedical portfolio includes various orthopedic products such as Formagraft, a bone graft substitute, and Formasetin, a bone void filler. For intra-articular applications in orthopedics, MBI markets injections under the names ArtiAid, ArtiAid Plus, and ArtiBest. The company's offerings also span both orthopedic and dental fields, featuring Foramic, a bone substitute granule; MaxiBone, a calcium phosphate ceramic; and GingivAid, a collagen dental graft. Specifically for dental use, MBI provides FormaAid, a collagen membrane, and the E-TECH DENTISTAR II sterilizer and disinfectant. Furthermore, HealiAid, a collagen wound dressing product, serves dental and general wound care purposes. MBI also manufactures ophthalmic viscoelastic devices, known as ViscAid, PreviscAid, and BiVisc, and produces Formaderm, a dermal filler injection utilized in plastic surgery. Beyond its medical devices, Maxigen Biotech Inc. offers a comprehensive line of skincare products. This array includes masks for the face, neck, body, and limbs, alongside make-up removers, cleansers, exfoliants, toners, essences, men's grooming items, sunscreens, and specialized body, hand, and foot care formulations. Maxigen Biotech Inc. was established in 1998 and operates from its main office in Taoyuan City, Taiwan.
- ISIN
- TW0001783009
- Founded
- 1998
- Listed since
- Oct 3, 2012
- Exchange
- Taiwan Stock Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.29 | +0.67% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.02 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.42 | +1.14% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $555.26 | +1.40% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $837.90 | +1.13% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $157.60 | +13.47% |
Figures last refreshed Aug 18, 2026.